secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001193125-25-061361
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen secures $175M PIPE for ophthalmology Wnt mimetics, drops liver program
-------------------------------------------------------------------------------

- Oversubscribed $175M private placement (two tranches: $70M initial, $105M contingent on FDA clearance) led by Venrock Healthcare Capital Partners.
- Prioritizes ophthalmology pipeline: lead candidates SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6) for retinopathies.
- Discontinues SZN-043 in severe alcohol-associated hepatitis due to insufficient clinical benefit signal relative to development path.
- Tim Kutzkey, Ph.D. joins Board of Directors; Series A/B warrant exercise prices reduced, Series C/D warrants cancelled.
- Funds multiple ophthalmology programs through Phase 1 safety, tolerability and efficacy studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000119312525061361/0001193125-25-061361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000119312525061361/d923940d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-061361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer